LL-37 is the 37-amino-acid C-terminal fragment of hCAP18, the only human cathelicidin antimicrobial peptide, encoded by the CAMP gene. It is part of the innate immune system—found in neutrophil granules, skin, gut epithelium, and airway secretions—and plays roles in direct antimicrobial activity, wound-healing signaling, and modulation of inflammatory responses. The FDA lists LL-37 on its compounding safety-risk register, and no approved injectable product exists in the US.

Safety note. This article is educational and for personal recordkeeping only. It gives no dose, unit count, concentration, reconstitution, injection technique, vendor, cycle, or stacking instructions. Peptide decisions, especially gray-market or research-use products, belong with a licensed professional.

What is LL-37?

LL-37 is an endogenous human peptide: not a synthetic molecule developed for a drug program, but a fragment the body naturally produces from the hCAP18 precursor. Its name reflects its structure—“LL” for the two leucines at its N-terminus, “37” for its amino acid length. In biology, LL-37 bridges antimicrobial defense and immune signaling; laboratory research has explored its activity against bacteria, biofilms, viruses, and wound-healing pathways.

The gap to flag: what LL-37 does at physiological concentrations in human tissue is very different from injecting a manufactured peptide at uncontrolled doses. The FDA’s compounding risk listing reflects the absence of safety and pharmacokinetic data for LL-37 as an injected drug. Gray-market “LL-37 for immune support” applies an endogenous signaling molecule with dose-dependent effects—including pro-inflammatory activity—outside any clinical framework. For a broader safety frame, read Research Peptide Safety Questions Before You Start.

What do people use LL-37 for?

People most often mention LL-37 for antimicrobial support, chronic infection stories, wound concerns, and immune-modulation stacks. Those are community claims, not proof. The same claim can mean very different things depending on whether it comes from a clinical label, a small trial, an animal model, a vendor page, or a forum anecdote.

Use the claim as a filing label, not a conclusion. Write down the purpose in plain language: what outcome is being watched, what else changed at the same time, and what would count as a reason to stop and ask for care.

How do people discuss using LL-37?

Reported use usually means research-use products and infection-focused forum discussions that can drift into treating serious medical problems without oversight. The useful part to record is context, not numbers: why it was considered, who reviewed it, what else was already in the stack, and what stop signs were discussed.

Do not copy online calculators, vendor protocols, or preparation walkthroughs into a personal plan. A peptide protocol log should preserve professional guidance and observations, not turn a social post into instructions.

What does the research say?

FDA safety material lists cathelicidin LL-37 among substances with insufficient safety information and notes nonclinical concerns that make casual use especially inappropriate.

A good research note separates mechanism, animal data, human trial data, approval status, and real-world anecdotes. When those buckets get mixed together, a peptide can look more proven than it is.

What should a beginner track?

Track medical diagnosis, symptoms, temperature, photos for clinician review, medications, and the threshold for urgent care rather than online troubleshooting.

In Dosefi, keep the entry boring and complete: date, category, source type, professional guidance, symptoms, photos only when useful, and the question you want answered next. A clear log is not proof that the peptide works. It is a way to avoid rewriting the story after the fact.

What red flags matter most?

Infection symptoms, wounds, fever, spreading redness, immune suppression, and antimicrobial resistance questions belong with medical care, not self-directed peptide experiments.

Also pause when a product is sold only through anonymous vendors, when a blend hides individual ingredients, when the seller offers medical claims without medical oversight, or when the only evidence is a before-and-after post. Serious symptoms should be handled as health events, not as content to troubleshoot in comments.

Sources